N-Glycan Profile of Cerebrospinal Fluids from Alzheimer's Disease Patients Using Liquid Chromatography with Mass Spectrometry

Byeong Gwan Cho, Lucas Veillon, Yehia Mechref

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Glycosylation, an essential post-translational protein modification, is known to be altered in a variety of diseases, including neurodegenerative diseases such as Alzheimer's disease (AD), which is one of the most common neurodegenerative disorders that results in cognitive and memory impairments. To investigate the progression of such a condition, cerebrospinal fluid (CSF), a unique biofluid that may possess significant biochemical and neurochemical changes due to the disease, is utilized. However, due to the low concentration of proteins in CSF, a large volume of the biofluid is often required to comprehensively characterize the glycome in CSF. In this work, a glycomic study of CSF was performed using as little as 10 μL of CSF. This approach was executed with permethylation of released N-glycans with minimal sample cleanup, in conjunction with an online purification system attached to liquid chromatography and a high-resolution mass spectrometer. This technique was then applied to clinical samples. Preliminary data suggest that fucosylated and bisecting GlcNAc structures were higher in abundances in females with AD, while both females and males exhibited lower abundances of high-mannose structures. Although there seems to be statistically significant differences between disease state and disease-free CSF, due to the lack of number of samples, further validation study should be conducted.

Original languageEnglish
Pages (from-to)3770-3779
Number of pages10
JournalJournal of Proteome Research
Volume18
Issue number10
DOIs
StatePublished - Oct 4 2019

Keywords

  • Alzheimer's disease
  • LC-MS
  • cerebrospinal fluid
  • glycomics
  • permethylation
  • reverse-phase separation

Fingerprint Dive into the research topics of 'N-Glycan Profile of Cerebrospinal Fluids from Alzheimer's Disease Patients Using Liquid Chromatography with Mass Spectrometry'. Together they form a unique fingerprint.

Cite this